ArticleThe journal of allergy and clinical immunology. Global2026
Severe eosinophilia and risk of major disease and mortality: A nationwide cohort study of children and adults.
Article in The journal of allergy and clinical immunology. Global, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Severe eosinophilia (SE), defined as greater than 5000 cells/μL, is uncommon but may indicate serious underlying disease. Its long-term prognostic implications across age groups remain unclear. Objectives: We sought to investigate the long-term risk of morbidity and all-cause mortality in children and adults with SE. Methods: We conducted a nationwide, population-based, matched cohort study using data from Clalit Health Services, Israel (2000-2023). Individuals with SE (n = 3822) were matched 1:10 to subjects without SE with normal eosinophil counts (<500/μL; n = 39,005). Five-year risks of cancer, autoimmune disease, thromboembolic events, allergic disorders, and all-cause mortality were assessed using multivariable Cox proportional hazards models. Results: The study included 42,827 participants, both with and without SE. Among the 29,289 adults, 2,497 had SE and 26,792 did not. Among the 13,538 children, 1,325 had SE and 12,213 did not. Among adults, SE was associated with increased risk of hematologic malignancy (hazard ratio [HR], 2.86; 95% CI, 1.88-4.36), autoimmune disease (HR, 1.64; 95% CI, 1.38-1.95), thromboembolic events (HR, 1.91; 95% CI, 1.45-2.53), and mortality (HR, 2.20; 95% CI, 1.84-2.62). In children, SE predicted solid tumors (HR, 14.24; 95% CI, 2.39-85.00), autoimmune disease (HR, 2.48; 95% CI, 1.97-3.12), allergic disorders (HR, 1.45; 95% CI, 1.26-1.67), and markedly increased mortality (HR, 7.95; 95% CI, 3.23-19.56). Conclusions: Severe eosinophilia is a strong prognostic marker in both children and adults, associated with malignancy, autoimmune and thromboembolic disease, and premature death. Recognition of SE should prompt comprehensive evaluation and close follow-up in general and specialty caregivers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.